AU2003235256A1 - Phenylalanine derivative - Google Patents

Phenylalanine derivative

Info

Publication number
AU2003235256A1
AU2003235256A1 AU2003235256A AU2003235256A AU2003235256A1 AU 2003235256 A1 AU2003235256 A1 AU 2003235256A1 AU 2003235256 A AU2003235256 A AU 2003235256A AU 2003235256 A AU2003235256 A AU 2003235256A AU 2003235256 A1 AU2003235256 A1 AU 2003235256A1
Authority
AU
Australia
Prior art keywords
phenylalanine derivative
phenylalanine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003235256A
Inventor
Eri Arai
Hiroko Kusaka
Haruhiko Manabe
Satoshi Nakanishi
Yoshisuke Nakasato
Akira Ogawa
Kiminori Ohta
Osamu Saku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of AU2003235256A1 publication Critical patent/AU2003235256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2003235256A 2002-04-19 2003-04-18 Phenylalanine derivative Abandoned AU2003235256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-117841 2002-04-19
JP2002117841 2002-04-19
PCT/JP2003/004970 WO2003089410A1 (en) 2002-04-19 2003-04-18 Phenylalanine derivative

Publications (1)

Publication Number Publication Date
AU2003235256A1 true AU2003235256A1 (en) 2003-11-03

Family

ID=29243507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003235256A Abandoned AU2003235256A1 (en) 2002-04-19 2003-04-18 Phenylalanine derivative

Country Status (3)

Country Link
JP (1) JPWO2003089410A1 (en)
AU (1) AU2003235256A1 (en)
WO (1) WO2003089410A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047759A1 (en) 2003-09-26 2006-02-22 Vertex Pharma FENIL DERIVATIVES - PIPERAZINE AS MODULATORS OF MUSCARNIC RECEPTORS
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
KR20070029733A (en) 2004-06-04 2007-03-14 제넨테크, 인크. Method for treating multiple sclerosis
KR101274879B1 (en) * 2004-12-20 2013-06-14 에자이 알앤드디 매니지먼트 가부시키가이샤 Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine
US7410971B2 (en) 2004-12-24 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CN101360711A (en) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-phenylalanine derivatives and its application as integrin antagonists
ES2684821T3 (en) 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
AR059224A1 (en) 2006-01-31 2008-03-19 Jerini Ag COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
AR060901A1 (en) 2006-05-12 2008-07-23 Jerini Ag HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008064823A1 (en) * 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
US20080182842A1 (en) * 2007-01-29 2008-07-31 Astrazeneca Ab L-alanine derivatives as a5beta1 antagonists
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9273027B2 (en) 2010-02-24 2016-03-01 Research Triangle Institute Arylpiperazine opioid receptor antagonists
EP2585446A4 (en) * 2010-06-22 2013-12-25 Shionogi & Co Compounds having trpv1 antagonistic activity and uses thereof
RU2634896C2 (en) * 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл New glp-1 receptor modulators
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140119777A (en) 2012-01-31 2014-10-10 제넨테크, 인크. Anti-ig-e m1' antibodies and methods using same
WO2013161904A1 (en) * 2012-04-24 2013-10-31 味の素株式会社 Sulfonamide derivative and medicinal use thereof
EP3008056B8 (en) 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
WO2015048819A1 (en) * 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
PT3064491T (en) 2013-10-29 2020-02-20 Ea Pharma Co Ltd Sulfonamide derivative and medicinal use thereof
JP2017538711A (en) * 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル GLP-1 receptor modulator
JP2018515424A (en) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Anti-alpha V beta 1 integrin inhibitors and methods of use
JP2018529747A (en) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド Methods for treating multiple sclerosis
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CN112969504B (en) 2018-10-30 2024-04-09 吉利德科学公司 Compounds for inhibiting alpha 4 beta 7 integrin
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233013B1 (en) * 1999-11-18 2007-02-28 Ajinomoto Co., Inc. Novel phenylalanine derivatives

Also Published As

Publication number Publication date
JPWO2003089410A1 (en) 2005-08-25
WO2003089410A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
AU2003235256A1 (en) Phenylalanine derivative
AU2002354224A1 (en) Novel phenylalanine derivative
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003231370A1 (en) Amide derivatives
AU2003231459A1 (en) Pyrimidine derivative
AU2003235889A1 (en) Amide derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2003288012A1 (en) Isothiazolyl-benzoxazine derivatives
AU2003208685A1 (en) Podologic aid
AU2002318053A1 (en) Suplier
AU2003243397A1 (en) Homo-camptothecin derivatives
AU2003284704A1 (en) Substituted 1h-pyridine-2-one derivatives
AU2003261875A1 (en) Amine derivative
AU2003264722A1 (en) Methods
AU2003227258A1 (en) Benzodiazepine derivative
AU2003217800A1 (en) Synthetic derivatives
AU2003292595A1 (en) Benzodiazepine derivative

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase